Background: The majority of NSCLC patients are diagnosed with stage IV disease. With the development of targeted therapies for advanced NSCLC, it has become important to understand which patients are being treated with systemic therapies and to what benefit. Method: We conducted a longitudinal, population-level study to determine the treatment patterns and survival in patients with stage IV NSCLC in Ontario, Canada between April 1, 2010 and March 31, 2015 from the Ontario Cancer Registry (OCR). Individuals were further identified as having non-squamous disease, and those who received an EGFR-TKI (afatinib, erlotinib, gefitinib) were assumed to be EGFR mutation-positive (EGFR+). Survival was calculated from date of diagnosis to death. Result: 24,729 individuals were diagnosed with NSCLC. Approximately half (12,159; 49.2%) had stage IV disease, including 10,103 with non-squamous disease, of whom 508 were categorized as EGFR+. The mean age for the stage IV non-squamous and EGFR+ cohorts were 68.7±11.0 years and 69.1±10.4 years, respectively; 49.3% and 60.8% were female, respectively. The most frequent treatments for stage IV non-squamous patients were palliative radiotherapy (RT) (46.7%) and systemic therapy (14.9%). Patients received no treatment in 26.7% of cases. 75.6% of the EGFR+ cohort received gefitinib, with the majority receiving no subsequent treatment (44.6%). Of EGFR+ patients receiving a second-line treatment, 20.1% received palliative RT and 18.7% received chemotherapy. Mean and median survival times (IQR) for the stage IV nonsquamous patients were 0.9±0.0 years and 0.4 (0.2-1.0) years, respectively. Substantial variation in survival was noted by treatment ( Figure 1 ). Mean and median survival times (IQR) for the EGFR+ cohort were 1.9±0.1 years and 1.5 (0.9-3.0) years, respectively. Figure  1 . Kaplan-Meier survival curves for stage IV non-squamous NSCLC patients based on treatment Conclusion: Relatively few patients with stage IV non-squamous NSCLC receive any systemic therapy. Survival is generally very poor, but best in the subgroup of EGFR+ patients. Keywords: Real World Evidence, treatment patterns, non small cell lung cancer P1.15-29 Impact of Radiation Therapy Quality Assurance on Progression-Free and Overall Survival in Randomized Trials of Lung Cancer Y.Y. Soon, 1 A. Tan, 2 I. Ng, 1 T.H. Tan, 1 J.C.S. Tey 1 1 Radiation Oncology, National University Hospital, Singapore, Singapore/SG, 2 National University Hospital, Singapore, Singapore/SG Background: To evaluate if the estimates of treatment effect differ between randomized trials (RCTs) that reported radiation therapy quality assurance (RTQA) and RCTs, which did not report RTQA, for treatment of lung cancer (LC) [C1] using curative intent thoracic radiation therapy (TRT). Method: We searched MEDLINE for eligible meta-analyses (MAs) of RCTs of LC. For each trial in the selected MAs, we reviewed if RTQA was performed and extracted the hazard ratios (HR) with 95% confidence interval (CI) for progression-free (PFS) and overall survival (OS). We quantify the differences in the estimated intervention effect on PFS and OS by a ratio of HRs (rHRs): the HR for trials that performed RTQA to that of trials that did not perform or report RTQA. An rHR more than 1 would indicate a larger HR for trials that performed RTQA compared to trials that did not perform or report. We estimated a combined rHR across MAs using a random effects MA model. We performed a meta-regression analysis to adjust for potential confounders including cancer type, comparisons type, sample size and single-vs-multi center trial. Result: We included six MAs that comprised of six comparisons and 50 RCTs (22 reported RTQA; 28 did not). Trials that performed RTQA showed similar intervention effect on PFS (rHR 0.96, 95% CI 0.82 to 1.12, P value (P) ¼ 0.57, I squared (I 2 ) ¼ 0%) and OS (rHR 1.00, 95% CI 0.88 to 1.15, P ¼ 0.94, I 2 ¼ 0%) compared to trials that did not perform or report RTQA, with low heterogeneity across individual MAs. There was no significant change in the summary rHRs after adjusting for potential confounders. Conclusion: The conduct of RTQA did not modify the estimates of intervention effects on progression-free and overall survival in randomized trials of lung cancer treated with curative intent thoracic radiation therapy. Keywords: radiation therapy, clinical trials, Quality assurance P1.15-30 Survival of Patients with Advanced NSCLC Treated with First-Generation EGFR-TKIs at a Cancer Hospital in Thailand, 2011 Thailand, -2016 
